Sagimet Biosciences Financials - Benzinga

Sagimet Biosciences Inc

SGMTNASDAQ

Trade with Public

Trade with Public

$10.55

-0.20-1.86%

At close: Aug 28, 5:00 PM EST

$10.90

0.353.31%

After Hours: Aug 28, 4:27 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Sagimet Biosciences Financials

Sagimet Biosciences (SGMT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 18.75 percent increase over losses of $(0.32) per share

Benzinga Newsdesk

PRO
Sagimet Biosciences Q1 EPS $(0.33) Beats $(0.36) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 41.07 percent increase over losses of $(0.56) per share

Benzinga Newsdesk

PRO
Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.48) by 39.08 percent. This is a 42 percent increase over losses of $(0.50) per share from

Benzinga Newsdesk

PRO
Sagimet Biosciences Q3 EPS $(0.40) Beats $(0.42) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.44 percent. This is a 11.11 percent increase over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Sagimet Biosciences Q2 EPS $(0.32) Beats $(0.53) Estimate

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.53) by 39.74 percent. This is a 28 percent decrease over losses of $(0.25) per share from

Benzinga Newsdesk

PRO
Sagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M

Benzinga Newsdesk